MPM Oncology Impact Management »

Rapt Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $14M 398k 33.87

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Rapt Therapeutics

TCG Crossover Management
Fcpm Iii Services B.v.
Rtw Investments
Foresite Capital Management VI
Siren
Vanguard Group
OrbiMed Advisors
Frazier Life Sciences Management
Ikarian Capital
Braidwell
Soleus Capital Management
Nantahala Capital Management
Caligan Partners
State Street Corporation
Dr. Jeffrey R. Jay, M.D.

View all funds holding Rapt Therapeutics